Display options
Share it on
Full text links
Atypon

J Clin Oncol. 1992 Oct;10(10):1615-23. doi: 10.1200/JCO.1992.10.10.1615.

Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

A Bosly, B Coiffier, C Gisselbrecht, H Tilly, G Auzanneau, F Andrien, R Herbrecht, M Legros, Y Devaux, J Jaubert

Affiliations

  1. Cliniques Universitaires de Mont-Godinne, Yvoir, France.

PMID: 1383435 DOI: 10.1200/JCO.1992.10.10.1615

Abstract

PURPOSE: Of the 737 patients with aggressive lymphoma who were treated with the LNH-84 regimen, 244 with progressive disease after complete remission or partial response were analyzed retrospectively to determine the influence of intensive chemotherapy with bone marrow transplantation (BMT) on survival.

PATIENTS AND METHODS: Forty-four patients were treated with salvage chemotherapy, followed by autologous bone marrow transplantation (ABMT) in 40 and allogeneic BMT in four. The other 200 patients were treated with chemotherapy only.

RESULTS: Salvage treatment produced an objective response in 57% of the patients; 23% achieved a second complete remission. Median overall survival was longer for patients who were treated with ABMT than for those who were treated with chemotherapy only (12.4 v 6.7 months), as was median freedom from progression (FFP) survival (7.7 v 4 months). In multiparametric analysis, ABMT and normal initial lactic dehydrogenase (LDH) level were the primary parameters associated with longer survival. This is also true when (1) only patients younger than 60 years of age, (2) only patients who responded to salvage regimen, or (3) only patients with both conditions were included in the analysis. Patients who were not transplanted had a 1.69 to 2.26 relative risk of dying from their disease compared with those who were treated with intensive chemotherapy plus ABMT.

CONCLUSION: This study produced more evidence of the favorable impact of intensive chemotherapy with bone marrow rescue on survival in lymphoma patients who had relapsed.

Similar articles

Cited by

Sadanandan N, Shear A, Brooks B, Saft M, Cabantan DAG, Kingsbury C, Zhang H, Anthony S, Wang ZJ, Salazar FE, Lezama Toledo AR, Rivera Monroy G, Vega Gonzales-Portillo J, Moscatello A, Lee JY, Borlongan CV.
Front Mol Neurosci. 2021 Nov 24;14:749716. doi: 10.3389/fnmol.2021.749716. eCollection 2021.
PMID: 34899179

Sadanandan N, Shear A, Brooks B, Saft M, Cabantan DAG, Kingsbury C, Zhang H, Anthony S, Wang ZJ, Salazar FE, Lezama Toledo AR, Rivera Monroy G, Vega Gonzales-Portillo J, Moscatello A, Lee JY, Borlongan CV.
Front Mol Neurosci. 2021 Nov 24;14:749716. doi: 10.3389/fnmol.2021.749716. eCollection 2021.
PMID: 34899179

Substances

MeSH terms

Publication Types

LinkOut - more resources